DDInter1084 DDInter927
Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Lomefloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Lomefloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Lomefloxacin {u} (Compound) binds {v} (Gene) TOP2A
Lomefloxacin {u} (Compound) causes {v} (Side Effect) Potassium low
Lomefloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Daunorubicin
Lomefloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cytarabine
Lomefloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bisacodyl
Lomefloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methoxsalen
Lomefloxacin {u} may lead to a major life threatening interaction when taken with {v} Methylprednisolone
Lomefloxacin {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Lomefloxacin (Compound) resembles Moxifloxacin (Compound)
Lomefloxacin (Compound) binds TOP2A (Gene)
Lomefloxacin (Compound) causes Potassium low (Side Effect)
Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Daunorubicin
Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen
Lomefloxacin may lead to a major life threatening interaction when taken with Methylprednisolone
Lomefloxacin may lead to a major life threatening interaction when taken with Ivosidenib